Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA approved for treatment of HNSCC. Taking advanta...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 15; no. 1; pp. 19742 - 14
Main Authors: Bottomly, Daniel, Mathieson, Chase, Vigoda, Myles, Jeng, Sophia, Evans, Nathaniel, Anderson, Ashley, Blucher, Aurora, Lesch, Aletha, Zheng, Christina, Laderas, Ted, Jacobs, James, Kulesz-Martin, Molly, McWeeney, Shannon
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 05.06.2025
Nature Publishing Group
Nature Portfolio
Subjects:
631/114
692/4028/67/1536
692/4028/67/69
Antitumor drug screening assays
Cancer
Cancer therapies
Chemotherapy
Copy number
DNA Copy Number Variations
Genes
Genomics
Genomics - methods
Head and neck carcinoma
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - genetics
HNSCC
Humanities and Social Sciences
Humans
Immunotherapy
Leukemia
Multi-Omics
multidisciplinary
Mutation
Patients
PD-1 protein
Pembrolizumab
Precision Medicine
Science
Science (multidisciplinary)
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - drug therapy
Squamous Cell Carcinoma of Head and Neck - genetics
Squamous Cell Carcinoma of Head and Neck - pathology
Tumors
Multi-Omics
Antitumor drug screening assays
HNSCC
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA approved for treatment of HNSCC. Taking advantage of a high throughput inhibitor assay and computational tools originally showing success in leukemia, we designed and employed HNSCC-specific inhibitor panels that capture the diversity of aberrational pathways in HNSCC to test viable cells derived from patients’ HNSCC tumors. This provides a functional context to the multi-omic readouts conducted on these samples (mutations, protein expression and copy number alterations). In addition to generating these deeply characterized functional genomics datasets, we also developed additional visual analytics that have the potential to provide greater insight into HNSCC drug response patterns and potentially aid precision oncology tumor boards in evaluation and assessment of effective targeted therapeutic agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-025-03111-7